The latest outbreaks of emerging pathogens, such as Ebola or Zika, emphasize the importance of the rapid development of vaccines. However, being able to predict the efficacy of new vaccines remains a challenge in vaccine development. Scientists have now successfully assessed early on the longer-term immune response in humans after being vaccinated with the newly developed Ebola vaccine rVSV-ZEBOV.